Genentech’s drug, Xofluza, is the first approved antiviral drug designed specifically for patients with a high risk for serious flu complications. People with high risk include those with asthma, chronic lung disease, diabetes, heart disease, morbid obesity, or those over age 65. The FDA approved it Oct. 17.
Xofluza, an oral, single-dose medicine, was approved for treatment of acute, uncomplicated influenza in patients over age 12 last year.
Side effects of Xofluza include diarrhea, bronchitis, nausea, sinusitis and headache.
Read the full news release here.
More articles on pharmacy:
Novant Health leaders talk Walgreens partnership goals for 2020
Sanofi recalls heartburn drug over cancer risks
Cheating scandal prompts California to invalidate pharmacist test scores
More articles on pharmacy:
Novant Health to open health clinics inside Walgreens
GlaxoSmithKline recalls prescription heartburn drug globally
BIO CEO to step down at the end of 2020
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.